Pulmonary Drug Delivery Systems Market (2026 - 2033)

Pulmonary Drug Delivery Systems Market Summary

The global pulmonary drug delivery systems market size was valued at USD 58.3 billion in 2025 and is projected to grow from USD 60.9 billion in 2026 to USD 82.7 billion in 2033, at a CAGR of 4.6% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 30.0% in 2025. The growth is attributed to the rising prevalence of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis.

The significant increase in occurrence and rate of respiratory diseases has resulted in the growth of the number of patients, which has subsequently raised the demand for these systems. The increasing prevalence of air pollution is contributing to a higher incidence of respiratory diseases, including bronchitis, pneumonia, chronic obstructive pulmonary disease (COPD), and lung cancer, thereby driving demand for pulmonary drug delivery systems. Pulmonary drug delivery systems enable direct deposition of therapeutic agents into the lungs, improving local drug concentration, enhancing treatment efficacy, reducing systemic side effects, and offering potential for both respiratory and systemic disease management.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Furthermore, it is expected that technological advancements in the health sector is also driving the demand for pulmonary drug delivery systems. Limitations of traditional treatments, such as the late onset of action and low effectiveness, are projected to encourage the development of novel targeted drug delivery devices, thereby boosting growth during the forecast period. The development of modern-day inhalers, such as, pressurized metered-dose inhalers (pMDIs), modern-day inhalers, e.g., pressurized metered-dose inhalers (pMDIs), soft mist inhalers (SMIs), and jet and vibrating mesh nebulisers (VMNs) have propelled the market growth.

Analyst Perspective

The pulmonary drug delivery systems market is experiencing steady growth, driven by the rising prevalence of respiratory diseases, the growing demand for targeted drug delivery, and the increasing adoption of advanced inhalation therapies. Various medical practitioners are now employing pulmonary drug delivery systems to improve therapeutic efficiency, achieve rapid drug absorption, and increase patient compliance in treating patients with asthma, COPD, cystic fibrosis, and other respiratory disorders. With the growing demand for efficient and technologically advanced respiratory therapy, those companies which are emphasizing innovation and development of personalized drug delivery solutions have great future prospects in the market.

Product Insights

The inhalers segment accounted for the largest market share of over 60.0% in 2025. Unlike injectable therapies that circulate throughout the bloodstream, inhalers deliver medication directly to the lungs, enabling a faster onset of action while minimizing systemic side effects. Their portability, compact design, ease of use, and minimal preparation requirements make inhalers a preferred option for the long-term management of respiratory diseases.

The nebulizers segment is expected to register the fastest CAGR during the forecast period. The increasing use of nebulizers among patients who have difficulty in using other inhalation devices, such as young children, elderly individuals, and those with coordination issues is the major factor driving the market growth. According to a study published in National Institutes of Health, the use of nebulizers in young children is widespread, with a prevalence between 33% and 71% in children under the age of 12.

Application Insights

The chronic obstructive pulmonary disease (COPD) segment accounted for the largest market share in 2025. COPD is a progressive respiratory disease that requires continuous treatment and long-term disease management. Pulmonary drug delivery systems allow for the direct delivery of bronchodilators and inhaled corticosteroids into the lungs. These help in increasing the air flow and reducing the inflammation while limiting the side effects on other parts of the body. While there is no cure for COPD, inhalation treatments have an important role. For instance, in May 2024, Verona Pharma received U.S. Food and Drug Administration (FDA) approval for Ohtuvayre (ensifentrine) as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The approval marked the introduction of the first new inhaled therapeutic mechanism for COPD maintenance therapy in more than 20 years, underscoring continued innovation in respiratory disease treatment.

The asthma segment is projected to grow at the fastest CAGR during the forecast period. More patients with asthma are looking to avail themselves of medications that are portable, user-friendly, and easy to integrate into their schedules. Innovations in inhalation therapy through the use of dry powder inhalers (DPI) and metered-dose inhalers (MDI) have improved treatment compliance among others. Rising asthma prevalence, coupled with the increasing adoption of advanced inhaler technologies, is expected to drive segment growth. For instance, in January 2024, AstraZeneca announced the commercial availability of AIRSUPRA (albuterol/budesonide) in the U.S., following its approval by the U.S. Food and Drug Administration (FDA) as the first anti-inflammatory rescue inhaler indicated for asthma. The combination inhaler contains a bronchodilator and an inhaled corticosteroid to provide quick relief from symptoms while addressing airway inflammation.

End-use Insights

The hospitals & clinics segment dominated the market in 2025. Hospitals and clinics remain the primary settings for managing severe respiratory conditions that require careful monitoring and accurate medication administration. Healthcare professionals frequently utilize nebulizers to rapidly deliver high doses of medication, making them essential for treating acute COPD exacerbations, severe asthma attacks, and other critical respiratory conditions. The availability of specialized respiratory care and advanced inhalation technologies further supports the segment's leading market position.

The home care segment is expected to register the fastest CAGR during the forecast period. Growth in the elderly population and the increasing prevalence of chronic respiratory diseases are driving demand for home-based respiratory care. Pulmonary drug delivery systems enable patients to manage chronic conditions effectively at home with appropriate training and clinical guidance, reducing the need for frequent hospital visits. Increasing adoption of portable inhalers and home nebulizer systems, combined with the expanding availability of remote patient monitoring and home healthcare services, is expected to support segment growth.

Regional Insights

North America pulmonary drug delivery systems market dominated the global market with the largest revenue share of around 30.0% in 2025. The growing prevalence of chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), continues to drive demand for pulmonary drug delivery systems across the region.

To learn more about this report, Download Free Sample Report

U.S. Pulmonary Drug Delivery Systems Market Trends

The U.S. pulmonary drug delivery systems industry dominated the North American market with over 75.0% share in 2025, driven by the increasing burden of chronic respiratory diseases and associated mortality.

Europe Pulmonary Drug Delivery Systems Market Trends

Europe pulmonary drug delivery systems industry was identified as a lucrative region in 2025, driven by the growing geriatric population and increasing prevalence of chronic respiratory diseases such as asthma and COPD. As the elderly population expands, demand for inhalation therapies continues to increase due to the long-term management required for these conditions.

In addition, manufacturers are investing in advanced inhaler technologies and expanding production capabilities to meet growing demand. For instance, in March 2025, Chiesi Group announced the acquisition of a manufacturing site in Nerviano (Milan), Italy, with a planned investment of approximately USD 505.2 million through 2030 to establish an international center of excellence for the production of next-generation carbon-minimal inhalers, dry powder inhalers, and sterile biological products. The investment is expected to strengthen Europe's manufacturing capacity for advanced pulmonary drug delivery systems.

The UK pulmonary drug delivery systems industry is expected to grow steadily over the forecast period, supported by increasing adoption of home healthcare and community-based respiratory care. Home-based treatment reduces hospital admissions while enabling patients with chronic respiratory diseases to manage their conditions more conveniently. The growing awareness of inhalation therapies and improved patient adherence associated with pulmonary drug delivery systems are further contributing to market growth. In addition, the continued integration of digital health technologies into respiratory disease management is expected to support wider adoption of advanced inhalation devices.

Asia Pacific Pulmonary Drug Delivery Systems Market Trends

The Asia Pacific pulmonary drug delivery systems industry is anticipated to witness significant growth during the forecast period. Rising incidences of asthma, COPD, and allergic rhinitis, coupled with improving healthcare infrastructure, are expected to drive market expansion. Governments across the region are also implementing initiatives to improve respiratory disease awareness, strengthen early diagnosis, and expand access to respiratory healthcare services, supporting increased adoption of pulmonary drug delivery technologies.

China pulmonary drug delivery systems industry is expected to experience robust growth owing to its large patient population, increasing healthcare expenditure, and expanding access to respiratory care services. Compared with developed markets, China offers significant opportunities for manufacturers to expand the availability of inhalation therapies. Furthermore, domestic manufacturers are expanding inhalation drug delivery manufacturing capabilities in China.

Key Pulmonary Drug Delivery Systems Company Insights

Some key companies in pulmonary drug delivery systems industry include 3M, Cipla, AstraZeneca, Koninklijke Philips N.V., OMRON Healthcare, Inc., and others. Companies concentrate on addressing market gaps, creating new products, focusing on specific areas and engaging in mergers & acquisitions to increase their market presence.

• AstraZeneca is a multinational pharmaceutical and biotechnology company. The company focuses on chronic respiratory conditions like asthma and COPD, as well as immune-related disorders like lupus and provide drug methods and combinations with the goal of reaching disease modification and clinical remission.

Key Pulmonary Drug Delivery Systems Companies:

The following key companies have been profiled for this study on the pulmonary drug delivery systems market:

• 3M

• AstraZeneca

• GSK plc.

• Novartis AG

• Koninklijke Philips N.V.

• Boehringer Ingelheim International GmbH.

• Teva Pharmaceutical Industries Ltd.

• OMRON Healthcare, Inc.

• PARI GmbH

• Cipla

Recent Developments

• In June 2024, Bespak announced the expansion of its manufacturing capacity for low-global warming potential (low-GWP) pressurized metered-dose inhalers (pMDIs), including the installation of a new commercial filling line to support increasing global demand for sustainable inhalation therapies.

• In April 2024, Launch Therapeutics, Inc. and Teva Pharmaceutical Industries Ltd entered into a clinical collaboration agreement to accelerate Teva’s ICS-SABA (TEV-‘248) clinical research program.

Global Pulmonary Drug Delivery Systems Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pulmonary drug delivery systems market report by product, application, end-use, and region:

• Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Inhalers
  • Nebulizers
  • Accessories
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
  • Asthma
  • Cystic Fibrosis
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Allergic Rhinitis
  • Pulmonary Arterial Hypertension
  • Others
• End-use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospitals & Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Home Care
  • Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • KSA
    • UAE
    • South Africa
    • Kuwait